idarubicin
RxCUI 5650
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Idarubicin
Idarubicin or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake. Similar to other anthracyclines, it also induces histone eviction from chromatin. It belongs to the family of drugs called antitumor antibiotics. It is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia. It is used for treatment of acute lymphoblastic leukemia and chronic myelogenous leukemia in blast crisis. It is distributed under the trade names Zavedos (UK) and Idamycin (USA).
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Conditions being studied
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.